Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1546-170X
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial ; volume:28 ; number:6 ; day:3 ; month:6 ; year:2022 ; pages:1167-1177 ; date:6.2022
Nature medicine ; 28, Heft 6 (3.6.2022), 1167-1177, 6.2022
- Urheber
-
Padrón, Lacey J.
Maurer, Deena M.
O’Hara, Mark H.
O’Reilly, Eileen M.
Wolff, Robert A.
Wainberg, Zev A.
Ko, Andrew H.
Fisher, George
Rahma, Osama
Lyman, Jaclyn P.
Cabanski, Christopher R.
Yu, Jia Xin
Pfeiffer, Shannon M.
Spasic, Marko
Xu, Jingying
Gherardini, Pier Federico
Karakunnel, Joyson
Mick, Rosemarie
Alanio, Cécile
Byrne, Katelyn T.
Hollmann, Travis J.
Moore, Jonni S.
Jones, Derek D.
Tognetti, Marco
Chen, Richard O.
Yang, Xiaodong
Salvador, Lisa
Wherry, E. John
Dugan, Ute
O’Donnell-Tormey, Jill
Butterfield, Lisa H.
Hubbard-Lucey, Vanessa M.
Ibrahim, Ramy
Fairchild, Justin
Bucktrout, Samantha
LaVallee, Theresa M.
Vonderheide, Robert H.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41591-022-01829-9
- URN
-
urn:nbn:de:101:1-2022100320072795749858
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:31 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Padrón, Lacey J.
- Maurer, Deena M.
- O’Hara, Mark H.
- O’Reilly, Eileen M.
- Wolff, Robert A.
- Wainberg, Zev A.
- Ko, Andrew H.
- Fisher, George
- Rahma, Osama
- Lyman, Jaclyn P.
- Cabanski, Christopher R.
- Yu, Jia Xin
- Pfeiffer, Shannon M.
- Spasic, Marko
- Xu, Jingying
- Gherardini, Pier Federico
- Karakunnel, Joyson
- Mick, Rosemarie
- Alanio, Cécile
- Byrne, Katelyn T.
- Hollmann, Travis J.
- Moore, Jonni S.
- Jones, Derek D.
- Tognetti, Marco
- Chen, Richard O.
- Yang, Xiaodong
- Salvador, Lisa
- Wherry, E. John
- Dugan, Ute
- O’Donnell-Tormey, Jill
- Butterfield, Lisa H.
- Hubbard-Lucey, Vanessa M.
- Ibrahim, Ramy
- Fairchild, Justin
- Bucktrout, Samantha
- LaVallee, Theresa M.
- Vonderheide, Robert H.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Cost-Effectiveness of Nivolumab Plus Ipilimumab for the First-Line Treatment of Intermediate/Poor-Risk Advanced and/or Metastatic Renal Cell Carcinoma in Switzerland
First-line oxaliplatin-based chemotherapy and nivolumab for metastatic microsatellite-stable colorectal cancer—the randomised METIMMOX trial
Nivolumab for Metastatic Cutaneous Squamous Cell Carcinoma
Metastatic Merkel cell carcinoma response to nivolumab
Immunologic research
Enhanced IL-34 expression in Nivolumab-resistant metastatic melanoma
Erratum to: Metastatic Merkel cell carcinoma response to nivolumab
Immunologic and virologic failure after first-line NNRTI-based antiretroviral therapy in Thai HIV-infected children
Nivolumab plus Ipilimumab: A Novel First-Line Combination Immunotherapy for Unresectable Hepatocellular Carcinoma
Response to anti-PD1 therapy with nivolumab in metastatic sarcomas
Immune-Related Meningoencephalitis following Nivolumab in Metastatic Renal Cell Carcinoma
Pembrolizumab as first-line treatment for metastatic uveal melanoma
Cost-Effectiveness of Nivolumab Plus Ipilimumab for the First-Line Treatment of Intermediate/Poor-Risk Advanced and/or Metastatic Renal Cell Carcinoma in Switzerland
First-line oxaliplatin-based chemotherapy and nivolumab for metastatic microsatellite-stable colorectal cancer—the randomised METIMMOX trial
Nivolumab for Metastatic Cutaneous Squamous Cell Carcinoma
Metastatic Merkel cell carcinoma response to nivolumab
Immunologic research
Enhanced IL-34 expression in Nivolumab-resistant metastatic melanoma
Erratum to: Metastatic Merkel cell carcinoma response to nivolumab
Immunologic and virologic failure after first-line NNRTI-based antiretroviral therapy in Thai HIV-infected children
Nivolumab plus Ipilimumab: A Novel First-Line Combination Immunotherapy for Unresectable Hepatocellular Carcinoma
Response to anti-PD1 therapy with nivolumab in metastatic sarcomas
Immune-Related Meningoencephalitis following Nivolumab in Metastatic Renal Cell Carcinoma
Pembrolizumab as first-line treatment for metastatic uveal melanoma
Cost-Effectiveness of Nivolumab Plus Ipilimumab for the First-Line Treatment of Intermediate/Poor-Risk Advanced and/or Metastatic Renal Cell Carcinoma in Switzerland
First-line oxaliplatin-based chemotherapy and nivolumab for metastatic microsatellite-stable colorectal cancer—the randomised METIMMOX trial
Nivolumab for Metastatic Cutaneous Squamous Cell Carcinoma
Metastatic Merkel cell carcinoma response to nivolumab
Immunologic research
Enhanced IL-34 expression in Nivolumab-resistant metastatic melanoma
Erratum to: Metastatic Merkel cell carcinoma response to nivolumab
Immunologic and virologic failure after first-line NNRTI-based antiretroviral therapy in Thai HIV-infected children
Nivolumab plus Ipilimumab: A Novel First-Line Combination Immunotherapy for Unresectable Hepatocellular Carcinoma
Response to anti-PD1 therapy with nivolumab in metastatic sarcomas
Immune-Related Meningoencephalitis following Nivolumab in Metastatic Renal Cell Carcinoma